A review on the role of fatty acids in colorectal cancer progression

Hoxha, Malvina; Zappacosta, Bruno

doi:10.3389/fphar.2022.1032806

Cited by 9 publications

(8 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding membrane stability, it is important to note that membrane saturation and rigidity play a role in chemotherapy and drug resistance. Higher membrane saturation gives way to less oxidative stress induced by chemotherapy, and increased cholesterol increases membrane rigidity, thus decreasing its permeability to drug treatment [ 48 ]. Cancer cells increase lipogenesis and require more lipid modification to survive.…”

Section: Metabolic Reprogramming and Transitionmentioning

confidence: 99%

Cancer metabolism and carcinogenesis

Yang,

Shay,

Saba

et al. 2024

Exp Hematol Oncol

View full text Add to dashboard Cite

Metabolic reprogramming is an emerging hallmark of cancer cells, enabling them to meet increased nutrient and energy demands while withstanding the challenging microenvironment. Cancer cells can switch their metabolic pathways, allowing them to adapt to different microenvironments and therapeutic interventions. This refers to metabolic heterogeneity, in which different cell populations use different metabolic pathways to sustain their survival and proliferation and impact their response to conventional cancer therapies. Thus, targeting cancer metabolic heterogeneity represents an innovative therapeutic avenue with the potential to overcome treatment resistance and improve therapeutic outcomes. This review discusses the metabolic patterns of different cancer cell populations and developmental stages, summarizes the molecular mechanisms involved in the intricate interactions within cancer metabolism, and highlights the clinical potential of targeting metabolic vulnerabilities as a promising therapeutic regimen. We aim to unravel the complex of metabolic characteristics and develop personalized treatment approaches to address distinct metabolic traits, ultimately enhancing patient outcomes.

show abstract

Section: Metabolic Reprogramming and Transitionmentioning

confidence: 99%

Cancer metabolism and carcinogenesis

Yang,

Shay,

Saba

et al. 2024

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…Considering the role of FFAs in CRC progression, new pharmacological therapies can be developed by targeting FASN, an enzyme responsible for FFAs synthesis, which has been demonstrated to be overexpressed in CRC [ 121 ]. Consistent data revealed that de novo lipogenesis supported by FASN in the TME, supplies tumor cells with energy, which enhances their rapid proliferation.…”

Section: The Caas Role In Crc Progressionmentioning

confidence: 99%

“…FASN inhibition leads to a decrease in tumor progression through several mechanisms, such as alteration of plasma membrane structure, an increase in cancer cell apoptosis, decrease in palmitate synthesis, and inhibition of Wnt, Akt, and β-catenin oncogenic signaling pathways [ 122 ]. The first-generation of FASN inhibitors, such as Orlistat, C75, and cerulenin, were tested in preclinical studies in different types of cancers, such as mesothelioma, lung, breast, renal, and prostate cancers [ 5 , 121 , 123 ]. However, their antitumoral effect has been associated with several side effects, such as weight loss or anorexia [ 123 ].…”

Section: The Caas Role In Crc Progressionmentioning

confidence: 99%

“…However, their antitumoral effect has been associated with several side effects, such as weight loss or anorexia [ 123 ]. The potential therapeutic effect of FASN inhibitors in CRC is very limited [ 121 ]. In this regard, only TVB-3664, a new generation of FASN inhibitors, has been tested with no significant toxicity in CRC patient-derived xenograft models [ 120 ].…”

Section: The Caas Role In Crc Progressionmentioning

confidence: 99%

See 1 more Smart Citation

Multi-Faceted Role of Cancer-Associated Adipocytes in Colorectal Cancer

Grigoraș,

Amalinei

2023

Biomedicines

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most commonly diagnosed types of cancer, especially in obese patients, and the second cause of cancer-related death worldwide. Based on these data, extensive research has been performed over the last decades to decipher the pivotal role of the tumor microenvironment (TME) and its cellular and molecular components in CRC development and progression. In this regard, substantial progress has been made in the identification of cancer-associated adipocytes’ (CAAs) characteristics, considering their active role in the CCR tumor niche, by releasing a panel of metabolites, growth factors, and inflammatory adipokines, which assist the cancer cells’ development. Disposed in the tumor invasion front, CAAs exhibit a fibroblastic-like phenotype and establish a bidirectional molecular dialogue with colorectal tumor cells, which leads to functional changes in both cell types and contributes to tumor progression. CAAs also modulate the antitumor immune cells’ response and promote metabolic reprogramming and chemotherapeutic resistance in colon cancer cells. This review aims to report recent cumulative data regarding the molecular mechanisms of CAAs’ differentiation and their activity spectrum in the TME of CRC. A better understanding of CAAs and the molecular interplay between CAAs and tumor cells will provide insights into tumor biology and may open the perspective of new therapeutic opportunities in CRC patients.

show abstract

“…However, because the initial symptoms are not obvious, patients often have poor prognosis in the late stages, so that the 5-year overall patient survival rate is less than 15%. 2 Reducing the metastasis and recurrence in late-stage patients is of great significance. Immune checkpoints refer to a series of molecules that are expressed in the immune cells.…”

Section: Introductionmentioning

confidence: 99%

Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview

Li¹,

Xu²

2023

IJGM

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common diseases in the world. Tumor immunotherapy is an innovative cancer treatment that acts by activating the human body's autoimmune system. Immune checkpoint block has been shown to be effective in DNA deficient mismatch repair/microsatellite instability-high CRC. However, the therapeutic effect for proficient mismatch repair/ microsatellite stability patients still requires further study and optimization. At present, the main CRC strategy is to combine other therapeutic methods, such as chemotherapy, targeted therapy, and radiotherapy. Here, we review the current status and the latest progress of immune checkpoint inhibitors in the treatment of CRC. At the same time, we consider therapeutic opportunities for transforming cold to hot, as well as perspectives on possible future therapies, which may be in great demand for drug-resistant patients.

show abstract

A review on the role of fatty acids in colorectal cancer progression

Cited by 9 publications

References 146 publications

Cancer metabolism and carcinogenesis

Cancer metabolism and carcinogenesis

Multi-Faceted Role of Cancer-Associated Adipocytes in Colorectal Cancer

Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview

Contact Info

Product

Resources

About